WU-CART-007: This study will provide long-term follow-up for people who have received treatment with WU-CART-007 in a previous clinical trialA Long-Term Safety Follow-Up Study for Patients Treated With Anti-CD7 Allogeneic CAR-T Cells

Trial purpose

Long-term follow-up

Tumor type

Haematological

Age

12+

Trial acronym

WU-CART-007

Summary

In this study, participants will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.

No study drug will be administered in this study.

Participants will transition to this long-term follow up (LTFU) study when they meet the criteria for discontinuation from the main study or after completing 24 months of follow-up in the main study. Participants will be contacted every 6 months for the first 5 years following WU-CART-007 administration and then yearly, for up to 10 years.

Conditions

This trial is treating people with T-cell Acute Lymphoblastic Leukaemia or T-cell Lymphoblastic Lymphoma who have received WU-CART-007 in another clinical trial